Tina Marriott Sells 6,000 Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Stock

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Get Free Report) COO Tina Marriott sold 6,000 shares of Recursion Pharmaceuticals stock in a transaction dated Thursday, October 24th. The stock was sold at an average price of $6.31, for a total transaction of $37,860.00. Following the sale, the chief operating officer now owns 521,138 shares of the company's stock, valued at approximately $3,288,380.78. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Tina Marriott also recently made the following trade(s):

• On Thursday, September 26th, Tina Marriott sold 6,000 shares of Recursion Pharmaceuticals stock. The stock was sold at an average price of $7.00, for a total transaction of $42,000.00.
• On Thursday, August 29th, Tina Marriott sold 6,000 shares of Recursion Pharmaceuticals stock. The shares were sold at an average price of $7.56, for a total value of $45,360.00.

Recursion Pharmaceuticals Trading Up 6.0 %

Shares of Recursion Pharmaceuticals stock traded up $0.39 during trading hours on Monday, reaching $6.87. The stock had a trading volume of 4,496,351 shares, compared to its average volume of 5,710,931. The company has a current ratio of 6.07, a quick ratio of 6.07 and a debt-to-equity ratio of 0.04. Recursion Pharmaceuticals, Inc. has a 1 year low of $4.97 and a 1 year high of $15.74. The firm has a market capitalization of $1.93 billion, a price-to-earnings ratio of -4.26 and a beta of 0.80. The firm has a 50 day simple moving average of $6.72 and a two-hundred day simple moving average of $7.70.

Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last posted its quarterly earnings results on Thursday, August 8th. The company reported ($0.40) EPS for the quarter, missing the consensus estimate of ($0.35) by ($0.05). Recursion Pharmaceuticals had a negative net margin of 755.37% and a negative return on equity of 79.47%. The business had revenue of $14.42 million during the quarter, compared to analysts' expectations of $11.96 million. During the same quarter in the previous year, the business posted ($0.38) EPS. The company's quarterly revenue was up 30.9% on a year-over-year basis. As a group, equities research analysts anticipate that Recursion Pharmaceuticals, Inc. will post -1.58 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities research analysts have recently commented on RXRX shares. Leerink Partners lowered their price objective on Recursion Pharmaceuticals from $9.00 to $8.00 and set a "market perform" rating for the company in a research report on Tuesday, September 3rd. Needham & Company LLC lowered their price target on Recursion Pharmaceuticals from $16.00 to $11.00 and set a "buy" rating for the company in a report on Wednesday, September 4th. KeyCorp cut their price objective on shares of Recursion Pharmaceuticals from $16.00 to $12.00 and set an "overweight" rating on the stock in a report on Thursday, July 11th. Finally, Jefferies Financial Group lowered their target price on shares of Recursion Pharmaceuticals from $8.00 to $6.00 and set a "hold" rating for the company in a report on Tuesday, September 3rd. Four analysts have rated the stock with a hold rating and two have issued a buy rating to the company's stock. According to data from MarketBeat, Recursion Pharmaceuticals presently has a consensus rating of "Hold" and an average target price of $9.40.

Institutional Trading of Recursion Pharmaceuticals

Institutional investors have recently added to or reduced their stakes in the business. Allspring Global Investments Holdings LLC acquired a new position in shares of Recursion Pharmaceuticals during the third quarter worth about $25,000. GAMMA Investing LLC lifted its position in Recursion Pharmaceuticals by 1,588.4% during the 2nd quarter. GAMMA Investing LLC now owns 6,416 shares of the company's stock worth $48,000 after acquiring an additional 6,036 shares in the last quarter. Amalgamated Bank lifted its position in Recursion Pharmaceuticals by 52.4% during the 2nd quarter. Amalgamated Bank now owns 7,152 shares of the company's stock worth $54,000 after acquiring an additional 2,459 shares in the last quarter. San Luis Wealth Advisors LLC purchased a new position in Recursion Pharmaceuticals in the 3rd quarter worth approximately $69,000. Finally, Vontobel Holding Ltd. acquired a new stake in Recursion Pharmaceuticals in the third quarter valued at approximately $70,000. 89.06% of the stock is owned by hedge funds and other institutional investors.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.